Suprastin Becomes Georgian Consumers’ Favorite Allergy Remedy
Thousand Oaks, Calif. – Amgen (AMGN), in partnership with Allergan (AGN), announced that the U.S. Food and Drug Administration (FDA) had approved its biosimilar for Genentech (RHHBY)’s Avastin. The biosimilar, or generic biological drug, is Mvasi (bevacizumab-awwb), and was approved for a broad swath of cancer indications, including in combination with chemotherapy for non-squamous non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic carcinoma of the cervix.